Search
Wisconsin Paid Clinical Trials
A listing of 1263 clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1165 - 1176 of 1263
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Wisconsin is currently home to 1263 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Recruiting
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: AL Amyloidosis
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Columbia St. Mary's, Milwaukee, Wisconsin
Conditions: Breast Cancer
Muscle Function After Childbirth
Recruiting
This study will evaluate lower extremity and trunk neuromuscular control in 78 nulligravid and postpartum women. Participants will attend two experimental sessions, approximately 1 week apart, to assess neuromuscular function. Physical activity levels will also be assessed.
Gender:
FEMALE
Ages:
Between 20 years and 35 years
Trial Updated:
06/25/2024
Locations: Carroll University, Waukesha, Wisconsin
Conditions: Postpartum, Muscle Fatigue, Force Steadiness, Nulligravid, Muscle Weakness
Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes
Recruiting
This study will test the preliminary efficacy of a joint patient/informal caregiver telephone-delivered intervention that includes diabetes education; problem solving around social needs; and behavioral activation for older African Americans with poorly controlled type 2 diabetes by randomizing 100 patient/caregiver dyads to the Joint Home intervention (n=50) and usual care (n=50) arms.
The aims of the study are:
Aim 1: To test the preliminary efficacy of home-based, joint patient and caregive... Read More
Gender:
ALL
Ages:
Between 50 years and 120 years
Trial Updated:
06/24/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type 2 Diabetes
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Cholangiocarcinoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Recruiting
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this procedure poses physical risks to the patient. A tissue biopsy also needs to be recollected at various time points in order to assess if the patient is responding to treatment.
In this project, the inves... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Sarcoma
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Recruiting
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or discontinuation criteria are met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Madison, Wisconsin
Conditions: Neoplasms
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Mayo Clinic Health Systems - NW Wisconsin, Eau Claire, Wisconsin
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Recruiting
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin
Conditions: Anal Squamous Cell Carcinoma
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
Recruiting
The current study is a randomized multi-center clinical trial that investigates the role an intraoperative hearing monitoring system (electrocochleography) has on helping to save residual hearing in patients undergoing cochlear implantation (CI).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
06/05/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hearing Loss, Sensorineural, Hearing Loss, Hearing Loss, Bilateral
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
Recruiting
The study will be a multi-site, randomized, two-arm, controlled clinical trial using OsteoGen® Plug (Test) vs Freeze-dried Bone Allograft with collagen barrier (Control) for alveolar ridge preservation (ARP) in posterior extraction sites with intact buccal cortical plates.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: WisNova Institute of Dental Specialists, Kenosha, Wisconsin
Conditions: Nonterminal Premolar Needing Extraction